Navigation Links
Abaxis Reports Financial Performance for the First Quarter of Fiscal 2012
Date:7/28/2011

basic

22,681

22,211  Weighted average common shares outstanding - diluted

23,095

22,750ABAXIS, INC.Condensed Consolidated Balance Sheets(Unaudited and in thousands)June 30,March 31,20112011Current assets: Cash and cash equivalents

$
45,073

$
43,471 Short-term investments

16,691

25,981 Receivables, net

26,422

27,880 Inventories

18,608

19,814 Prepaid expenses and other current assets

3,854

3,496 Net deferred tax assets, current

3,430

3,422  Total current assets

114,078

124,064 Long-term investments

47,129

36,237 Investment in unconsolidated affiliate

2,731

2,769 Property and equipment, net

21,532

19,637 Intangible assets, net

4,067

4,216 Net deferred tax assets, non-current

1,203

1,203 Other assets

132

134  Total assets

$
90,872

$
88,260Current liabilities: Accounts payable

$
5,777

$
,173 Accrued payroll and related expenses

6,215

6,129 Accrued taxes

533

559 Other accrued liabilities

1,805

1,677 Deferred revenue

1,044

953 Warranty reserve

1,195

1,031  Total current liabilities

16,569

16,522Non-current liabilities: Deferred rent

478

416 Deferred revenue

1,958

1,737 Warranty reserve

275

191 Notes payable, less current portion

725

746  Total non-current liabilities

3,436

3,090  Total liabilities

20,005

19,612Shareholders' equity: Common stock

132,047

132,042 Retained earnings

38,820

36,606  Total shareholders' equity

170,867

168,648  Total liabilities and shareholders' equity

$
90,872

$
88,260Operating Income Per Share(In thousands, except per share da
'/>"/>

SOURCE Abaxis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Abaxis to Report First Quarter Fiscal Year 2012 Financial Results Thursday, July 28, 2011
2. Abaxis to Present at Jefferies 2011 Global Healthcare Conference
3. Abaxis to Present at ThinkEquitys Second Annual Healthcare Conference
4. Abaxis Receives Presidential "E" Award for Exports
5. Abaxis, Inc. Awarded $650,000 from Kansas Bioscience Authority
6. Abaxis, Inc. to Present at the Bank of America Merrill Lynch 2011 Health Care Conference
7. Abaxis Appoints Vernon Altman to Board of Directors
8. Abaxis to Report Fourth Quarter and Fiscal Year 2011 Financial Results Thursday, April 28, 2011
9. Abaxis, Inc. to Present at the 10th Annual Needham Healthcare Conference
10. Abaxis, Inc. to Present at RBC Capital Markets Healthcare Conference
11. Abaxis Reports Financial Performance With Record Sales for the Third Quarter of Fiscal 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Calif. , May 21, 2013 Abaxis, ... blood analysis systems, announced today that Martin ... at the Stifel Annual Dental & Veterinary Conference on ... conference will be held at Le Parker Meridien Hotel ... About Abaxis Abaxis develops, manufactures, markets ...
(Date:5/21/2013)... JUPITER, Fla. , May 21, 2013  BioRestorative ... a life sciences company focused on developing stem cell ... Mark Weinreb , its President and CEO, ... The conference will be held on Thursday, ... at 109 E 42nd Street in New York City.  ...
(Date:5/21/2013)... 2013 Ceregene, Inc. today announced additional ... double-blind, randomized, controlled Phase 2b clinical study of ... designed to deliver the neurotrophic factor neurturin, for ... robust response to CERE-120 in Parkinson,s patients diagnosed ... those diagnosed 10 years or more (p<.005), as ...
Breaking Medicine Technology:Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference 2BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 2BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 3Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 2Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 3Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 4Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 5
... Nov. 18, 2010 The Pharmacy Technician ... Melissa Murer Corrigan, will serve as the 2011 president ... be installed at the ICE Annual Education Conference on ... organization that provides educational, networking and advocacy resources for ...
... 2010 Cell Therapeutics, Inc. ("CTI") (Nasdaq and ... Application ("MAA") seeking approval for Pixuvri™ (pixantrone dimaleate) ... relapsed or refractory aggressive non-Hodgkin,s lymphoma ("NHL") was ... Medicines Agency ("EMA"). Validation indicates that the application ...
Cached Medicine Technology:Melissa Murer Corrigan to Serve as 2011 ICE President 2The European Medicines Agency Validates and Accepts Cell Therapeutics' Marketing Authorization Application for Pixuvri™ 2The European Medicines Agency Validates and Accepts Cell Therapeutics' Marketing Authorization Application for Pixuvri™ 3
(Date:5/21/2013)... May 21 (HealthDay News) -- Urban elementary school ... experience sleep problems and suffer academically, new research ... aged seven to nine, we found that compromised ... and impaired academic performance," said study author ... human behavior at Brown University,s Alpert Medical School ...
(Date:5/21/2013)... Minn. Positively charged gold nanoparticles are usually ... to avoid nanoparticle toxicity. Mayo Clinic researchers found ... nanoparticles effective against ovarian cancer cells. The discovery ... the Journal of Biological Chemistry ., "This ... cancer cells by preventing the cell death or ...
(Date:5/21/2013)... May 21, 2013 Representatives with Hammerhead Bicycles ... a success that the company has achieved its overall goal ... day one was to move Hammerhead Bicycles from a house ... President Scott Robertson. , Robertson explained that the bike shop ... to exclusively focus on all things 29er and 650b. ...
(Date:5/21/2013)... the sound of galloping hooves behind you, your immediate reaction ... it is actually a zebra approaching. Doctors are trained to ... their practices, and as they rarely or never meet a ... takes many years to reach the right diagnosis. A new ... many cases. , Ole Winther is Associate Professor at ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Two-thirds of ... non-small cell lung cancer reported that they engage in ... medicine use, according to new findings from the ... Kantar Health . The research will be presented ... (International Society for Pharmacoeconomics and Outcomes Research) in New ...
Breaking Medicine News(10 mins):Health News:Sleepless Nights May Hurt School Performance of Kids With Asthma 2Health News:Mayo Clinic: How gold nanoparticles can help fight ovarian cancer 2Health News:Hammerhead Bicycles Now a Standalone Brand 2Health News:New search engine finds rare diagnoses 2Health News:New search engine finds rare diagnoses 3Health News:Two in Three Cancer Patients are Non-Adherent with Their Medications, According to Kantar Health Research 2Health News:Two in Three Cancer Patients are Non-Adherent with Their Medications, According to Kantar Health Research 3
... Leuven - Jean-Christophe Marine (VIB, K.U.Leuven) strongly argues against the ... long time - been seen as an attractive drug target ... as a tumor suppressor, and thus inhibits tumor formation. His ... cancer drug targets. Tumorigenesis: loss of control ...
... March 15, 2011 Minor league hockey players in the ... a brain injury since bodychecking was first allowed among the ... Hospital neurosurgeon Dr. Michael Cusimano. The findings, published online ... growing evidence that bodychecking holds greater risk than benefit for ...
... by today,s high throughput DNA sequencing technology presents a ... handle the staggering amount of data, and, more importantly, ... experiment? Aside from the cost of the sequencing platforms ... to expand hardware and storage resources, but getting to ...
... carcinoma (HCC) have been increasing worldwide, and hepatitis ... in the pathogenesis of HCC. Previous studies have ... consumption, smoking, diabetes mellitus, and obesity, are important ... reported that HCV infection causes insulin resistance and ...
... well reported complication in chronic cholestatic liver disease such as ... deficiency has been addressed in many articles over the last ... alcoholic liver cirrhosis. A research article published on February ... addresses this question. The authors described the serum vitamin D ...
... Steven Reinberg HealthDay Reporter , MONDAY, March 14 ... not clear, but it now appears that it may be ... before it becomes evident, a new study suggests. This ... seen in people who do not develop Alzheimer,s disease, the ...
Cached Medicine News:Health News:New insights into cancer treatment 2Health News:Brain injuries rise sharply in minor hockey after bodychecking rules relaxed: Study 2Health News:mygenomatix: A secure cloud-like model for next-gen sequencing data analysis 2Health News:Mental Decline May Start Years Before Alzheimer's 2
... a Q-switched ruby laser system ... nm. High Performance Combined with ... combination of high performance and ... mode effectively destroys the (natural ...
A Powerful New Quantitative Immunoassay for Monitoring Bladder Cancer Patients. Useful in Monitoring Patients for,Disease Progression and Recurrence....
... Test is an in vitro immunoassay intended for ... tumor associated antigen. It is indicated for use ... cancer in conjunction with cystoscopy or when prescribed ... by the FDA for prescription home use in ...
... is a quantitative microplate enzyme immunoassay that detects ... have very small amounts of NMP22 protein in ... is often elevated in the urine of patients ... the disease. The use of the NMP22 protein ...
Medicine Products: